FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
[Federal Register: July 1, 1997 (Volume 62, Number 126)] [Notices] [Page 35513-35516] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr01jy97-94] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Care Financing Administration [HSQ-243-N] Medicare, Medicaid, and CLIA Programs; Clinical Laboratory Improvement Amendments of 1988 Continuance of Exemption of Laboratories Licensed by the State of Washington AGENCY: Health Care Financing Administration (HCFA), HHS. ACTION: Notice. ----------------------------------------------------------------------- [[Page 35514]] SUMMARY: This notice announces that laboratories located in the State of Washington that possess a valid license under the Medical Test Site Licensure Law, Chapter 70.40 of the Revised Code of Washington (RCW), continue to be exempt from the requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA) until April 30, 2001. DATES: The continuance granted by this notice is effective until April 30, 2001. FOR FURTHER INFORMATION CONTACT: Val Coppola, (410) 786-3531. SUPPLEMENTARY INFORMATION: I. Background and Legislative Authority Section 353 of the Public Health Service Act (PHS Act), as amended by the Clinical Laboratory Improvement Amendments of 1988 (CLIA), requires any laboratory that performs tests on human specimens to meet requirements established by the Department of Health and Human Services (HHS). Under the provisions of the sentence following section 1861(s)(14) and paragraph 1861(s)(16) of the Social Security Act, any laboratory that also wants to be paid for services furnished to Medicare beneficiaries must meet the requirements of section 353 of the PHS Act. Subject to specified exceptions, laboratories must have a current and valid CLIA certificate to test human specimens and to be eligible for payment from the Medicare or Medicaid programs. Regulations implementing section 353 of the PHS Act are contained in 42 CFR part 493. Section 353(p) of the PHS Act provides for the exemption of laboratories from CLIA requirements in a State that applies requirements that are equal to or more stringent than those of CLIA. The statute does not specifically require the promulgation of criteria for the exemption of laboratories in a State. The decision to grant CLIA exemption to laboratories within a State is at the discretion of HCFA, acting on behalf of the Secretary of HHS. Various regulations in 42 CFR part 493 subpart E implement section 353(p) of the PHS Act. Section 493.513 provides that HCFA may exempt from CLIA requirements, for a period not to exceed 6 years, all State licensed or approved laboratories in a State if the State meets specified conditions. Section 493.513(k) provides that we will publish a notice in the Federal Register announcing the names of States whose laboratories are exempt from meeting the requirements of part 493, describing the basis for granting the exemption, describing how the laboratory requirements are equal to or more stringent than those of CLIA, and specifing a term of approval not to exceed 6 years. On December 23, 1994 (59 FR 66314), we published a notice in the Federal Register announcing that the State of Washington had applied for exemption of its laboratories from CLIA requirements; that the evaluation of this application demonstrated that all requirements for exemption were met; and that Washington was granted an exemption. II. Requirements for Granting CLIA Exemption In order to determine whether we should grant or continue an existing CLIA exemption to laboratories within a State, we conduct a detailed and in-depth comparison of State and CLIA requirements to determine whether the State meets the requirements at Sec. 493.513. In summary, the State must: <bullet> Have laws in effect that provide for requirements that are equal to or more stringent than CLIA requirements; <bullet> Have an agency that licenses or approves laboratories that meet State requirements which meet or exceed CLIA requirements, and, therefore, meet the condition level requirements of the CLIA regulations; <bullet> Meet the requirements and be approved in accordance with Sec. 493.515, Federal review of laboratory requirements of State laboratory programs; <bullet> Demonstrate that it has enforcement authority and administrative structures and resources adequate to enforce its laboratory requirements; <bullet> Permit HCFA or HCFA agents to inspect laboratories within the State; <bullet> Require laboratories within the State to submit to inspections by HCFA or HCFA agents as a condition of licensure; <bullet> Agree to pay the cost of the validation program administered by HCFA and the cost of the State's pro rata share of the general overhead to develop and implement CLIA as specified in Secs. 493.645(b) and 493.646; and <bullet> Take appropriate enforcement action against laboratories found by HCFA or HCFA agents not to be in compliance with requirements comparable to condition level requirements. As specified in our regulations at Sec. 493.515, our review of a State laboratory program includes (but is not necessarily limited to) an evaluation of: <bullet> Whether the State's requirements for laboratories are equivalent to or more stringent than the condition level requirements; <bullet> The State's inspection process requirements to determine: --The comparability of the full inspection and complaint inspection procedures to those of HCFA; --The State's enforcement procedures for laboratories found to be out of compliance with its requirements; and --The ability of the State to provide HCFA with electronic data and reports with the adverse or corrective actions resulting from proficiency testing (PT) results that constitute unsuccessful participation in HCFA-approved PT programs and with other data HCFA determines to be necessary for validation and assessment of the State's inspection process requirements; <bullet> The State's agreement with HCFA to ensure that the agreement obligates the State to: --Notify HCFA within 30 days of the action taken against any CLIA- exempt laboratory that has had its licensure or approval withdrawn or revoked or been in any way sanctioned; --Notify HCFA within 10 days of any deficiency identified in a CLIA- exempt laboratory in cases when the deficiency poses an immediate jeopardy to the laboratory's patients or a hazard to the general public; --Notify each laboratory licensed by the State within 10 days of HCFA's withdrawal of the exemption; --Provide HCFA with written notification of any changes in its licensure (or approval) and inspection requirements; --Disclose any laboratory's PT results in accordance with a State's confidentiality requirements; --Take the appropriate enforcement action against laboratories found by HCFA not to be in compliance with requirements comparable to condition level requirements and report these enforcement actions to HCFA; --Notify HCFA of all newly licensed laboratories, including the specialties and subspecialties for which any laboratory performs testing, within 30 days; and --Provide HCFA, as requested, inspection schedules for validation purposes. III. Evaluation of the Washington Request for Continued CLIA Exemption Washington has applied to HCFA for continued exemption of its laboratories from CLIA requirements. We evaluated the request for continuation of the Washington CLIA exemption for equivalency against the three major categories of CLIA rules: the [[Page 35515]] implementing regulations, the enforcement regulations, and the deeming/ exemption requirements. We evaluated the application to verify Washington's assurance of continued compliance with the following subparts of part 493: Subpart A, General Provisions; Subpart E, Accreditation by a Private, Nonprofit Accreditation Organization or Exemption Under an Approved State Laboratory Program; Subpart H, Participation in Proficiency Testing for Laboratories Performing Tests of Moderate Complexity (Including the Subcategory), High Complexity, or Any Combination of These Tests; Subpart M, Personnel for Moderate and High Complexity Testing; Subpart P, Quality Assurance for Moderate or High Complexity Testing, or Both; Subpart Q, Inspection; and Subpart R, Enforcement Procedures. Washington was found to continue to meet the requirements of Subparts A, E, H, M, P, Q, and R. IV. Validation Inspections The Federal validation inspections of CLIA-exempt laboratories, as specified in Sec. 493.517, were conducted on a representative sample basis as well as in response to any substantial allegations of noncompliance (complaint inspections). The outcome of those validation inspections has been and will continue to be HCFA's principal tool for verifying that the laboratories located in and licensed by the State are in compliance with CLIA requirements. HCFA staff of the Laboratory Survey Section, Division of Health Standards and Quality in the HCFA Regional Office in Seattle, Washington have conducted validation inspections of a representative sample (approximately 5 percent) of the laboratories inspected by the Washington Office of Laboratory Quality Assurance (LQA). The validation inspections were of the concurrent type; that is, HCFA surveyors accompanied Washington's surveyors, each inspecting against his or her agency's respective regulations. Analysis of the validation data revealed no significant differences between the State and Federal findings. The Washington inspection process covers all appropriate CLIA conditions and the State laboratory licensure requirements were found to meet or exceed CLIA requirements. The HCFA survey staff found the State inspectors highly skilled and qualified. The LQA is maintaining its workload at the proper level to assure that all laboratories within the State will be inspected in a 24-month cycle. All parameters monitored by HCFA staff to date indicate that the LQA is meeting all requirements under the CLIA exemption. This Federal monitoring will continue as an on-going process. The CLIA exemption of laboratories located in and licensed by Washington may be removed if we determine the outcome and comparability review of validation inspections are not acceptable as described under Sec. 493.521 or if Washington fails to pay the required fee every 2 years as required under Sec. 493.646. V. Laboratory Data In accordance with Sec. 493.513(d)(2)(iii), Washington will continue to agree to provide us with changes to a laboratory's specialties or subspecialties based on the State's survey. Washington also will provide us with changes in a laboratory's certification status, such as a change from a regular certificate to a certificate of waiver. VI. Required Administrative Actions CLIA is intended to be a totally user-fee funded program. The registration fee paid by laboratories is intended to cover the cost of the development and administration of the program. However, when a State's application for exemption is approved, we may not charge a fee to laboratories in the State. The State's share of the costs associated with CLIA must be collected from the State. Section 493.645 specifies that HHS will assess fees such that the costs of administering the CLIA program will be shared by all States including those that are CLIA exempt. Washington must pay for: <bullet> Costs of Federal inspection of laboratories in the State to verify that standards are enforced in an appropriate manner. The average Federal hourly rate is multiplied by the total hours required to perform Federal validation surveys within the State. <bullet> Costs incurred for Federal investigations and surveys triggered by complaints that are substantiated. We will bill Washington on a semiannual basis. <bullet> Washington's proportionate share of the costs associated with establishing, maintaining, and improving the CLIA computer system, a portion of those services from which Washington received direct benefit or contributed to the CLIA program in the State. Thus, Washington is being charged for a portion of HCFA's direct and indirect costs as well as a portion of the costs incurred by the Centers for Disease Control and Prevention (CDC). In order to estimate Washington's proportionate share of the general overhead costs to develop and implement CLIA, we determined the ratio of laboratories in the State to the total number of laboratories nationally. Approximately 1.6 percent of the registered laboratories are in Washington. We determined that 1.6 percent of the applicable CDC and HCFA costs should be borne by Washington. Washington has agreed to pay us the State's pro rata share of the overhead costs and anticipated costs of actual validation and complaint investigation surveys. A final reconciliation for all laboratories and all expenses will be made. We will reimburse the State for any overpayment or bill it for any balance. VII. Approval HCFA grants continuance of the CLIA exemption for all specialties and subspecialties to all laboratories located in and licensed by the State of Washington effective July 1, 1997 to April 30, 2001. VIII. Regulatory Impact Statement We generally prepare a regulatory flexibility analysis that is consistent with the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 through 612) unless the Secretary certifies that a notice such as this would not have a significant economic impact on a substantial number of small entities. For purposes of the RFA, we consider all laboratories to be small entities. Also, section 1102(b) of the Act requires the Secretary to prepare a regulatory impact analysis for any notice that may have a significant impact on the operations of a substantial number of small rural hospitals. Such an analysis must conform to the provisions of section 604 of the RFA. For purposes of section 1102(b) of the Act, we consider a small rural hospital as a hospital that is located outside of a Metropolitan Statistical Area and has fewer than 50 beds. This notice announces the continuance of the exemption of laboratories licensed by the State of Washington from the requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The State has established that the quality of laboratory services continues to meet standards equivalent to or more stringent than those of the CLIA program and also has established that it has a comparable program to monitor and evaluate compliance with the standards. The effect of the continued exemption from CLIA requirements is that laboratories will remain under State, rather than Federal, regulation, with no discernible difference in the [[Page 35516]] operations of the programs. Consequently, we anticipate that our continuation of Washington's CLIA exemption will not affect the laboratories or the quality and availability of services provided. Therefore, we have determined, and the Secretary certifies, that this notice will not result in a significant impact on a substantial number of small entities and will not have a significant effect on the operations of a substantial number of small rural hospitals. Therefore, we are not preparing analyses for either the RFA or section 1102(b) of the Act. In accordance with the provisions of Executive Order 12866, this notice was not reviewed by the Office of Management and Budget. Authority: Section 353(p) of the Public Health Service Act (42 U.S.C. 263a). Dated: May 30, 1997. Bruce C. Vladeck, Administrator, Health Care Financing Administration. [FR Doc. 97-17193 Filed 6-30-97; 8:45 am] BILLING CODE 4120-01-P |
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH